Crispr Therapeutics is currently experiencing a surge in call options trading, with volume exceeding the expected levels at 1.3 times the norm. The implied volatility has also seen a significant increase, now standing at 55.13%.
The most active options are the January 2025 50 calls and the December 2024 47 calls, accounting for almost 1,300 contracts.
The Put/Call Ratio for Crispr Therapeutics is notably low at 0.20, indicating a bullish sentiment among investors. Earnings are anticipated to be reported on February 19th, which may have an additional impact on trading activity.